Atria Investments Inc Has $61,000 Stock Position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Atria Investments Inc grew its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 44.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 40,421 shares of the company’s stock after buying an additional 12,430 shares during the quarter. Atria Investments Inc’s holdings in Milestone Pharmaceuticals were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Valeo Financial Advisors LLC increased its stake in Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after acquiring an additional 10,000 shares during the period. Lion Point Capital LP lifted its position in shares of Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock valued at $3,089,000 after acquiring an additional 40,000 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Milestone Pharmaceuticals by 177.0% during the 1st quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,800 shares in the last quarter. 86.18% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MIST. Rodman & Renshaw assumed coverage on Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They issued a “buy” rating and a $9.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Monday, October 14th.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock opened at $1.84 on Monday. The business has a fifty day simple moving average of $1.58 and a 200 day simple moving average of $1.52. The company has a market cap of $98.12 million, a P/E ratio of -2.27 and a beta of 1.72. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals Inc. has a twelve month low of $1.12 and a twelve month high of $3.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. On average, sell-side analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.